Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What fueled the previous growth in the varizig market?
In recent times, the varizig market size has seen a XX (HCAGR). Projected growth figures indicate an increase from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. Factors contributing to this growth during the historic period include rising healthcare expenditure, an increasing number of organ transplantation procedures, elevated government funding for immunization programs, a rise in the elderly population, and an increase in private insurance coverage.
What will be the varizig market size in the future?
The market size for varizig is projected to witness a XX (FCAGR) increase in the upcoming years, with an expected value of $XX million by 2029, equating to a compound annual growth rate (CAGR) of XX%. This forecasted growth can be linked to factors such as the increasing occurrence of chickenpox, an influx of investment into varicella-related biological development, a rising demand for immune globulin products, the expansion of public health initiatives, and an increase in clinical trials. The key trends expected during the forecast period involve technological innovations, global humanitarian adoption, progress in recombinant DNA technology, the creation of new formulations, and the proliferation of telemedicine.
Get your varizig market report here!
https://www.thebusinessresearchcompany.com/report/varizig-global-market-report
What main drivers are fueling expansion in the varizig market?
The projected upsurge in varicella-zoster virus infections is anticipated to bolster the varizig market. The highly infectious varicella-zoster virus (VZV) is responsible for causing chickenpox initially, and can potentially reactivate later, causing shingles (herpes zoster). The escalating number of varicella-zoster virus (VZV) infections, which result in conditions like chickenpox and shingles, is linked to declining vaccination rates, an aging populace, and immune suppression caused by medical treatments. Varizig aids varicella-zoster virus patients by providing passive immunity, reducing the severity and duration of chickenpox symptoms, preventing complications in high-risk groups such as immunocompromised patients, and providing protection against severe consequences in newborns and expectant women exposed to the virus. As a case in point, the Florida Department of Health, a US governmental agency, reported that the number of varicella cases rose to 653 in 2023, a distinct rise from 428 cases in 2022. Consequently, the escalating occurrence of varicella-zoster virus infections propels the varizig market.
What key areas define the segmentation of the global varizig market?
The varizig market covered in this report is segmented –
1) By Patient Condition: Immunocompromised Patients; Pregnant Women
2) By Distribution Channel: Hospitals; Pharmacies; Healthcare Providers
3) By End User: Adult; Geriatric; Pediatric
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20448&type=smp
Who are the dominant players expanding their reach in the varizig market?
Major companies operating in the varizig market are Emergent BioSolutions Inc.
How are evolving market trends shaping varizig Strategies?
Securing supply agreements for at-risk patient groups, expanding distribution networks, and catering to the increasing needs for passive immunization, especially in urgent and high-risk situations, is defining the major trend in the varizig market. These supply agreements are agreements stipulating the terms of product or service provision, including costs, delivery timelines, and responsibilities. For example, in July 2022, Israel’s biopharmaceutical company, Kamada Ltd., announced a $11.4 million deal to supply its product VARIZIG to an undisclosed organization majorly involved in Latin America. The provision is set to occur from the fourth quarter of 2022 to the first half of 2023. This pact demonstrates Kamada’s aim to boost the sales of its FDA-endorsed plasma-derived therapies globally, underlining the market potential beyond North America. Specifically, VARIZIG is used for post-exposure varicella (chickenpox) prophylaxis in vulnerable groups such as immunocompromised patients and newborns, establishing it as an essential treatment option for these demographics.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20448
Which regions are emerging as leaders in the varizig market?
North America was the largest region in the varizig market in 2024. The regions covered in the varizig market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Cold Plasma Global Market Report 2025
https://thebusinessresearchcompany.com/report/cold-plasma-global-market-report
Porcine Plasma Feed Global Market Report 2025
https://thebusinessresearchcompany.com/report/porcine-plasma-feed-global-market-report
Plasma Fractionation Global Market Report 2025
https://thebusinessresearchcompany.com/report/plasma-fractionation-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
